The FDA approved risankizumab-rzaa for children aged at least 6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy or active psoriatic arthritis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results